Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

15.08
-0.1600-1.05%
Volume:60.89K
Turnover:923.72K
Market Cap:2.63B
PE:-5.32
High:15.36
Open:15.26
Low:15.08
Close:15.24
52wk High:34.47
52wk Low:12.72
Shares:174.32M
Float Shares:66.98M
Volume Ratio:0.32
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8352
EPS(LYR):-2.7303
ROE:-77.58%
ROA:-47.07%
PB:4.32
PE(LYR):-5.52

Loading ...

How Argenx's 'Blowout' Quarter Sparked A Blazing 31% Monthlong Run

Blockhead
·
Aug 15

Immunovant Is Maintained at Overweight by JP Morgan

Dow Jones
·
Aug 12

U.S. RESEARCH ROUNDUP-Advanced Drainage Systems, Assurant, Chipotle Mexican Grill

Reuters
·
Aug 12

Stifel Nicolaus Sticks to Their Buy Rating for Immunovant (IMVT)

TIPRANKS
·
Aug 12

Immunovant price target lowered to $57 from $58 at Citi

TIPRANKS
·
Aug 12

Immunovant’s IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs

TIPRANKS
·
Aug 12

Immunovant's Fiscal Q1 Net Loss Widens

MT Newswires Live
·
Aug 11

Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.68 Loss

MT Newswires Live
·
Aug 11

Immunovant Q1 Net Income USD -120.613 Million

Reuters
·
Aug 11

Immunovant Q1 EPS $(0.71), Inline

Benzinga
·
Aug 11

Immunovant Q1 Basic EPS USD -0.71

THOMSON REUTERS
·
Aug 11

Immunovant Q1 Operating Expenses USD 127.224 Million

THOMSON REUTERS
·
Aug 11

Immunovant Inc. Appoints Eric Venker as New CEO with Comprehensive Compensation Package

Reuters
·
Jul 30

Immunovant Is Maintained at Neutral by UBS

Dow Jones
·
Jul 29

Immunovant price target raised to $18 from $17 at UBS

TIPRANKS
·
Jul 28

Immunovant (IMVT) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
Jul 27

Immunovant Inc. CTO Jay Stout Reports Disposal of Common Shares

Reuters
·
Jul 26

Eric Venker, President & Immunovant CEO, Reports Disposal of Common Shares in Roivant Sciences Ltd

Reuters
·
Jul 24

Jay S. Stout, Chief Technology Officer of Immunovant Inc., Reports Disposal of Common Shares

Reuters
·
Jul 12

Goldman Sachs Resumes Coverage with a Hold Rating on Immunovant (IMVT)

TIPRANKS
·
Jul 10